PERSONALIZED APPROACH TO THE TREATMENT OF CARDIOVASCULAR DISEASES
Keywords:
Keywords: personalized medicine, cardiovascular diseases, pharmacogenomics, artificial intelligence, biomarkers, risk stratification, targeted therapy.Abstract
Abstract: Cardiovascular diseases (CVD) remain the leading cause of mortality worldwide. The traditional treatment strategy based on standardized protocols often fails to account for individual genetic, phenotypic, and metabolic characteristics of the patient, leading to reduced therapy efficacy and the development of side effects. This article discusses the concept of personalized medicine (PM) as a new standard of cardiac care. Modern approaches are analyzed, including pharmacogenomics, the application of artificial intelligence (AI) for "omics" data analysis, and the use of multimodal imaging. It is shown that the integration of these methods allows for patient risk stratification, optimization of lipid-lowering and anticoagulant therapy selection, and prediction of surgical intervention outcomes. Special attention is paid to the challenges of implementing PM into routine clinical practice, including economic barriers and the need to create large biobanks.
References
1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248.
3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722
4. UT S. Kh. RF Dry whey: a promising product for the food industry and agriculture //Web of Teachers: Inderscience Research. – 2025. – Т. 3. – №. 3. – С. 16-18
5. Улмасов Т. Ш. Применение искусственного интеллекта в клинической микробиологии: новые горизонты диагностики // Лучшие интеллектуальные исследования. – 2026. – Т. 65. – №. 1. – С. 246-252.
6. Улмасов Т. Ш. Гайморит, Причины, Симптомы и Профилактика Лечения // TADQIQOTLAR jahon ilmiy-metodik jurnali. – 2025. – Т. 56. – №. 1. – С. 204-206.
7. Улмасов Т. Ш. Современные подходы к диагностике, профилактике и хирургическому лечению ишемической болезни сердца // "YURT FAXRI". – 2025. – Т. 1. – №. 1.
8. Ulmasov T. Sh. Prevention of Thyroid Diseases // 10. – 2024. – Т. 2. – №. 2. – С. 144-146.
9. Улмасов Т. Ш. О роли витаминов в жизненном цикле человека // Journal of Healthcare and Life-Science Research. – 2024. – Т. 3. – №. 1.
10. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
11. Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol. 2017;69(21):2657-2664.
12. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-209.
13. Holmes MV, Assimes TL, Karpe F. Polygenic risk scores in cardiovascular disease: a clinical perspective. J Am Coll Cardiol. 2019;74(1):111-118.
14. Collins R, Reith C, Emberson J, et al. Interpretation of the clinical efficacy and safety of statin therapy: an independent meta-analysis of data from large trials. Lancet. 2016;388(10059):2532-2561.
15. Zhao Y, Ye Y, Wang Y, et al. Artificial intelligence-driven cardiovascular precision medicine: from multi-omics to clinical application. Brief Bioinform. 2023;24(2):bbad042.
